Wed, September 15, 2010
[ Wed, Sep 15th 2010 ] - Market Wire
Qtrax Beta Available in India
Tue, September 14, 2010
Mon, September 13, 2010
Sun, September 12, 2010
Fri, September 10, 2010
Thu, September 9, 2010
Wed, September 8, 2010
Tue, September 7, 2010
Sat, September 4, 2010
[ Sat, Sep 04th 2010 ] - Market Wire
Transdel Pharmaceuticals
Fri, September 3, 2010
Thu, September 2, 2010
Wed, September 1, 2010
Tue, August 31, 2010
Mon, August 30, 2010
Sun, August 29, 2010
Fri, August 27, 2010
[ Fri, Aug 27th 2010 ] - Market Wire
?????????????????????
Thu, August 26, 2010
Wed, August 25, 2010
Tue, August 24, 2010

RXi Pharmaceuticals to Webcast Presentation at the Rodman & Renshaw Global Investment Conference


//health-fitness.news-articles.net/content/2010/ .. rodman-renshaw-global-investment-conference.html
Published in Health and Fitness on Tuesday, September 7th 2010 at 9:41 GMT by Market Wire   Print publication without navigation


WORCESTER, Mass.--([ BUSINESS WIRE ])--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Companya™s President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the Rodman & Renshaw Global Investment conference on Monday, September 13, 2010 at 2:50 p.m. ET in New York City.

A live webcast of the presentation will be available on the aInvestorsa section of the Company's website, [ www.rxipharma.com ]. A replay of the presentation will be available for 30 days.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals is a recognized leader in RNAi-based therapeutic discovery and development with a comprehensive therapeutic platform that includes both RNA interference (RNAi) compounds and delivery methods. The company is leveraging this broad and integrated RNAi therapeutic platform to build a pipeline of RNAi therapeutics for the treatment of a number of disease areas, including its core focus of developing treatments for anti-scarring and retinal disorders as well as a continued interest in oncology and indications accessible by spinal cord delivery. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi therapeutics market based on the strength of its next generation therapeutic platform, experienced management team, accomplished Scientific Advisory Board, including Nobel Laureate, Dr. Craig Mello, and its broad intellectual property position in RNAi chemistry and delivery. [ www.rxipharma.com ]


Publication Contributing Sources